These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
977 related items for PubMed ID: 15356308
1. Thiazolidinediones. Yki-Järvinen H. N Engl J Med; 2004 Sep 09; 351(11):1106-18. PubMed ID: 15356308 [No Abstract] [Full Text] [Related]
3. Polycystic ovary syndrome and insulin resistance. Plosker SM. Med Health R I; 2003 Jan 09; 86(1):12-5. PubMed ID: 12633015 [No Abstract] [Full Text] [Related]
4. Insulin resistance and PPAR insulin sensitizers. Bhatia V, Viswanathan P. Curr Opin Investig Drugs; 2006 Oct 09; 7(10):891-7. PubMed ID: 17086933 [Abstract] [Full Text] [Related]
5. [Oral therapy in type 2 diabetes. Critical evaluation of glitazones]. Lotz N. MMW Fortschr Med; 2002 Jan 24; 144(3-4):48-50. PubMed ID: 11862793 [No Abstract] [Full Text] [Related]
8. [The PPARgamma receptor agonists and prevention of cardio-vascular complications in patients with type 2 diabetes. The results of the PROactive study]. Szymborska-Kajanek A, Strojek K. Kardiol Pol; 2006 Mar 24; 64(3):322-5; discussion 325-6. PubMed ID: 16583340 [No Abstract] [Full Text] [Related]
9. [New antidiabetic in "virtual reality". Eye to eye with insulin resistance]. MMW Fortschr Med; 2000 May 11; 142(19):52. PubMed ID: 10850084 [No Abstract] [Full Text] [Related]
14. Use of metformin in pediatric age. Brufani C, Fintini D, Nobili V, Patera PI, Cappa M, Brufani M. Pediatr Diabetes; 2011 Sep 24; 12(6):580-8. PubMed ID: 21366813 [No Abstract] [Full Text] [Related]
15. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus. Irons BK, Greene RS, Mazzolini TA, Edwards KL, Sleeper RB. Pharmacotherapy; 2006 Feb 24; 26(2):168-81. PubMed ID: 16466323 [Abstract] [Full Text] [Related]
16. A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes. Lehmann DF, Lohray BB. J Clin Pharmacol; 2008 Aug 24; 48(8):999-1002. PubMed ID: 18650500 [No Abstract] [Full Text] [Related]
17. Cardiovascular risk in women with polycystic ovary syndrome. Cho LW, Atkin SL. Minerva Endocrinol; 2007 Dec 24; 32(4):263-73. PubMed ID: 18091663 [Abstract] [Full Text] [Related]
18. [Glitazones more than hypoglycemics in type 2 diabetes]. Sjöholm A. Lakartidningen; 2007 Dec 24; 104(43):3201-3. PubMed ID: 18018938 [No Abstract] [Full Text] [Related]
19. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. Omer Z, Cetinkalp S, Akyildiz M, Yilmaz F, Batur Y, Yilmaz C, Akarca U. Eur J Gastroenterol Hepatol; 2010 Jan 24; 22(1):18-23. PubMed ID: 19667999 [Abstract] [Full Text] [Related]
20. [Too positive comment on glitazones]. Lindberg M. Ugeskr Laeger; 2007 Feb 19; 169(8):733; author reply 733. PubMed ID: 17338040 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]